BVS – bioventus inc. - class a (US:NASDAQ)

News

Pressure Ulcers Treatment Markets, 2024-2028 & 2033 [Yahoo! Finance]
Bioventus Inc. (NYSE: BVS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $15.00. They now have a "buy" rating on the stock.
Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... [Yahoo! Finance]
Bioventus (BVS) Matches Q3 Earnings Estimates [Yahoo! Finance]
Bioventus: Q3 Earnings Snapshot [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com